{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:30:11Z","timestamp":1769153411375,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hepatitis C virus (HCV) infection remains a public health concern, significantly affecting vulnerable populations including people who use drugs and in prisons. This study assessed the feasibility of a new prison-based test-and-treat model for HCV in two prisons in Kedah, Malaysia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The model was tested on participants newly admitted between June 2022 and December 2023 to one of the two selected prisons, one for pretrial detention and the other for serving sentences. It features a streamlined test-and-treat procedure within prisons, encompassing anti-HCV (exposure) testing, HCV ribonucleic acid (RNA) (current infection) testing, pretreatment assessments, and treatment initiation. The outcome assessment focused on (I) screening coverage, (II) implementation success across the HCV care cascade, ranging from anti-HCV detection, HCV RNA confirmation, treatment initiation, and completion to a sustained virological response rate and (III) practicality within resource-limited prison environments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>All 18,811 (100%) newly admitted participants were screened for HCV during the study period, with 4,054 (21.6%) of them testing positive for anti-HCV (HCV exposure). A total of 793 (19.6%) participants underwent HCV RNA testing, with 655 (82.6%) confirmed to have HCV infection. Those with HCV RNA test results were mainly male (98.1%), with nearly half (48.2%) aged 40\u201349 years. A vast majority (95.7%) reported at least one HCV risk factor, primarily injection drug use (95.2%). Of the 655 participants with a positive HCV RNA test, 648 (98.9%) completed pretreatment assessments. Antiviral treatment was initiated in 319 (49.2%) of them, with 165 (51.7%) completing the full course. Among those who completed treatment, 80 (48.5%) underwent HCV RNA testing 12 weeks after treatment, with 77 (96.3%) achieving a sustained virologic response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This new prison-based test-and-treat model for HCV infection demonstrates promising feasibility, as indicated by high screening coverage and successful implementation across the HCV care cascade using existing resources. These findings suggest the potential for broader adoption of this model in correctional facilities. Further research is needed to improve treatment completion and address factors contributing to dropout.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12889-025-22296-0","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T19:33:36Z","timestamp":1743017616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Feasibility of a prison-based test-and-treat model for enhancing hepatitis C care in Kedah, Malaysia"],"prefix":"10.1186","volume":"25","author":[{"given":"Mohd Azri Mohd","family":"Suan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Muaz","family":"Zulkifli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor Hidayati","family":"Ani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azlina","family":"Azlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad Faiz","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siti Maisarah Md","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siti Aishah","family":"Aris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Aisyah Sakinah Muhamad","family":"Nizar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatihah Fahami Mohd Najib","family":"Fahami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amizah","family":"Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-Keat","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Radzi Abu","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"22296_CR1","unstructured":"World Health Organization. Global hepatitis report 2024: Action for access in low- and middle-income countries. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240091672. Accessed 8 Feb 2025."},{"key":"22296_CR2","unstructured":"World Health Organization, Hepatitis C. Fact Sheet. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 6 June 2024."},{"key":"22296_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101249","author":"M Khatun","year":"2019","unstructured":"Khatun M, Ray RB. Mechanisms underlying hepatitis C virus-associated hepatic fibrosis. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8101249.","journal-title":"Cells"},{"key":"22296_CR4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.039","author":"Z Younossi","year":"2016","unstructured":"Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.039.","journal-title":"Gastroenterology"},{"key":"22296_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30579-7","author":"JD Stanaway","year":"2016","unstructured":"Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016. https:\/\/doi.org\/10.1016\/S0140-6736(16)30579-7.","journal-title":"Lancet"},{"key":"22296_CR6","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2017\u20132021. 2016. https:\/\/www.who.int\/publications\/i\/item\/WHO-HIV-2016.06. Accessed 13 July 2024."},{"key":"22296_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad344","author":"M Martinello","year":"2023","unstructured":"Martinello M, Naggie S, Rockstroh JK, Matthews GV. Direct-acting antiviral therapy for treatment of acute and recent hepatitis C virus infection: a narrative review. Clin Infect Dis. 2023. https:\/\/doi.org\/10.1093\/cid\/ciad344.","journal-title":"Clin Infect Dis"},{"key":"22296_CR8","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v14.i6.1053","author":"II Salama","year":"2022","unstructured":"Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, et al. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol. 2022. https:\/\/doi.org\/10.4254\/wjh.v14.i6.1053.","journal-title":"World J Hepatol"},{"key":"22296_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12051255","author":"W Tang","year":"2022","unstructured":"Tang W, Tao Y, Fajardo E, Reipold EI, Chou R, Tucker JD, et al. Diagnostic accuracy of point-of-care HCV viral load assays for HCV diagnosis: a systematic review and meta-analysis. Diagnostics. 2022. https:\/\/doi.org\/10.3390\/diagnostics12051255.","journal-title":"Diagnostics"},{"key":"22296_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00346-6","author":"A Trickey","year":"2023","unstructured":"Trickey A, Fajardo E, Alemu D, Artenie AA, Easterbrook P. Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1016\/S2468-1253(22)00346-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"22296_CR11","volume-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018."},{"key":"22296_CR12","unstructured":"Ministry of Health Malaysia. National strategic plan for hepatitis B and C 2019\u20132023. 2019. https:\/\/www.moh.gov.my\/moh\/resources\/Penerbitan\/Pelan%20Strategik%20\/NSP_Hep_BC_2019_2023.pdf?gh_jid=4958715003. Accessed 13 July 2024."},{"key":"22296_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30769-3","author":"A Kamarulzaman","year":"2016","unstructured":"Kamarulzaman A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet. 2016. https:\/\/doi.org\/10.1016\/S0140-6736(16)30769-3.","journal-title":"Lancet"},{"key":"22296_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055142","author":"J Markby","year":"2021","unstructured":"Markby J, Shilton S, Sem X, Chan HK, Said RM, Siva S, et al. Assessing the impact of simplified HCV care on linkage to care amongst high-risk patients at primary healthcare clinics in Malaysia: a prospective observational study. BMJ Open. 2021. https:\/\/doi.org\/10.1136\/bmjopen-2021-055142.","journal-title":"BMJ Open"},{"key":"22296_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229143","author":"R Castro","year":"2020","unstructured":"Castro R, Perazzo H, de Araujo LAMM, Gutierres IG, Grinsztejn B, Veloso VG. Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: a systematic review with meta-analysis. PLoS ONE. 2020. https:\/\/doi.org\/10.1371\/journal.pone.0229143.","journal-title":"PLoS ONE"},{"key":"22296_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-023-00458-3","author":"JL Calleja","year":"2024","unstructured":"Calleja JL, Espin J, Kaushik A, Hernandez-Guerra M, Blissett R, Yehoshua A, et al. The efficiency of increased HCV testing and treatment strategies in Spain to achieve elimination goals. Pharmacoecon Open. 2024. https:\/\/doi.org\/10.1007\/s41669-023-00458-3.","journal-title":"Pharmacoecon Open"},{"key":"22296_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30427","author":"J Mera","year":"2020","unstructured":"Mera J, Williams MB, Essex W, McGrew KM, Boeckman L, Gahn D, et al. Evaluation of the Cherokee Nation hepatitis C virus elimination program in the first 22 months of implementation. JAMA Netw Open. 2020. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.30427.","journal-title":"JAMA Netw Open"},{"key":"22296_CR18","doi-asserted-by":"publisher","unstructured":"Avramovic G, O\u2019Doherty L, McHugh T, Remy AJ, Happiette A, Bouchkira H et al. Benchmarking of an intervention aiming at the micro-elimination of hepatitis c in vulnerable populations in Perpignan, France, to inform scale-up and elimination on the French Territory. Viruses. 2024; https:\/\/doi.org\/10.3390\/v16101645","DOI":"10.3390\/v16101645"},{"key":"22296_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11050877","author":"J Cabezas","year":"2021","unstructured":"Cabezas J, Llerena S, Mateo M, \u00c1lvarez R, Cobo C, Gonz\u00e1lez V, et al. Hepatitis C micro-elimination beyond prison walls: navigator-assisted test-and-treat strategy for subjects serving non-custodial sentences. Diagn. 2021. https:\/\/doi.org\/10.3390\/diagnostics11050877.","journal-title":"Diagn"},{"key":"22296_CR20","unstructured":"Ministry of Health Malaysia. Clinical practice guidelines: management of chronic hepatitis C in adults. 2019. https:\/\/www.moh.gov.my\/moh\/resources\/Penerbitan\/CPG\/Gastroenterology\/CPG_Management_of_Chronic_Hepatitis_ C_in_ Adults.pdf. Accessed 6 June 2024."},{"key":"22296_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24612-9","author":"MAM Suan","year":"2022","unstructured":"Suan MAM, Chan HK, Sem X, Shilton S, Hassan MRA. Diagnostic performance of two non-invasive biomarkers used individually and in sequential combination for cirrhosis associated with hepatitis C virus infection. Sci Rep. 2022. https:\/\/doi.org\/10.1038\/s41598-022-24612-9.","journal-title":"Sci Rep"},{"key":"22296_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00800-2","author":"MRA Hassan","year":"2023","unstructured":"Hassan MRA, Chan HK, Nordin M, Yahya R, Sulaiman WRW, Merican SAA, et al. Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs. Harm Reduct J. 2023. https:\/\/doi.org\/10.1186\/s12954-023-00800-2.","journal-title":"Harm Reduct J"},{"key":"22296_CR23","volume-title":"R: A Language and environment for statistical computing","author":"R Core Team","year":"2014","unstructured":"R Core Team. R: A Language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014."},{"key":"22296_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.012","author":"T Papaluca","year":"2019","unstructured":"Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, et al. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. J Hepatol. 2019. https:\/\/doi.org\/10.1016\/j.jhep.2019.01.012.","journal-title":"J Hepatol"},{"key":"22296_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.019","author":"Y Sheehan","year":"2023","unstructured":"Sheehan Y, Cunningham EB, Cochrane A, Byrne M, Brown T, McGrath C, et al. A \u2018one-stop-shop\u2019 point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study. J Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.019.","journal-title":"J Hepatol"},{"key":"22296_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckv133","author":"C Rumble","year":"2015","unstructured":"Rumble C, Pevalin DJ, O\u2019Moore \u00c9. Routine testing for blood-borne viruses in prisons: a systematic review. Eur J Public Health. 2015. https:\/\/doi.org\/10.1093\/eurpub\/ckv133.","journal-title":"Eur J Public Health"},{"key":"22296_CR27","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0617","author":"T He","year":"2016","unstructured":"He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, et al. Prevention of hepatitis C by screening and treatment in U.S. Prisons. Ann Intern Med. 2016. https:\/\/doi.org\/10.7326\/M15-0617.","journal-title":"Ann Intern Med"},{"key":"22296_CR28","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51854","author":"RJ Winter","year":"2023","unstructured":"Winter RJ, Sheehan Y, Papaluca T, Macdonald GA, Rowland J, Colman A, et al. Consensus recommendations on the management of hepatitis C in Australia\u2019s prisons. Med J Aust. 2023. https:\/\/doi.org\/10.5694\/mja2.51854.","journal-title":"Med J Aust"},{"key":"22296_CR29","doi-asserted-by":"publisher","DOI":"10.1108\/IJPH-07-2016-0028","author":"MD Morris","year":"2017","unstructured":"Morris MD, Brown B, Allen SA. Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health. Int J Prison Health. 2017. https:\/\/doi.org\/10.1108\/IJPH-07-2016-0028.","journal-title":"Int J Prison Health"},{"key":"22296_CR30","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.107372","author":"HK Chan","year":"2020","unstructured":"Chan HK, Hassali MA, Said RM, Hassan MRA. Treatment coverage and drug expenditure in hepatitis C patients from 2013 to 2019: a journey of improving treatment accessibility in Malaysia through government-led initiatives. Hepat Mon. 2020. https:\/\/doi.org\/10.5812\/hepatmon.107372.","journal-title":"Hepat Mon"},{"key":"22296_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00357-0","author":"MWL Cheong","year":"2021","unstructured":"Cheong MWL, Piedagnel JM, Khor SK. Ravidasvir: equitable access through an alternative drug development pathway. Lancet Glob Health. 2021. https:\/\/doi.org\/10.1016\/S2214-109X(21)00357-0.","journal-title":"Lancet Glob Health"},{"key":"22296_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00031-5","author":"I Andrieux-Meyer","year":"2021","unstructured":"Andrieux-Meyer I, Tan SS, Thanprasertsuk S, Salvadori N, Men\u00e9trey C, Simon F, et al. Efficacy and safety of Ravidasvir plus Sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2\/3 trial. Lancet Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1016\/S2468-1253(21)00031-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"22296_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad104","author":"D Adda","year":"2023","unstructured":"Adda D, James C, Peck R, Ali M, Tiwana T, Kolawole T, et al. The role of nonprofit and nongovernmental organizations and people with viral hepatitis on the path toward hepatitis C virus elimination. J Infect Dis. 2023. https:\/\/doi.org\/10.1093\/infdis\/jiad104.","journal-title":"J Infect Dis"},{"key":"22296_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/wfs2.1473","author":"C Norman","year":"2023","unstructured":"Norman C. A global review of prison drug smuggling routes and trends in the usage of drugs in prisons. WIREs Forensic Sci. 2023. https:\/\/doi.org\/10.1002\/wfs2.1473.","journal-title":"WIREs Forensic Sci"},{"key":"22296_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104027","author":"L Favril","year":"2023","unstructured":"Favril L. Drug use before and during imprisonment: drivers of continuation. Int J Drug Policy. 2023. https:\/\/doi.org\/10.1016\/j.drugpo.2023.104027.","journal-title":"Int J Drug Policy"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-22296-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-22296-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-22296-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T19:33:48Z","timestamp":1743017628000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-22296-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22296"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-22296-0","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received approval from the Medical Research and Ethics Committee, Ministry of Health Malaysia (NMRR-24-02267-1HZ), in accordance with the ethical standards of the 1964 Helsinki Declaration. Requirement for participants informed consent was waived according to national regulations (NIH Guidelines for Conducting Research in Ministry of Health Institutions & Facilities, 3rd Edition, 2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1152"}}